Increased endothelin-1 (ET-1) and reduced endothelial nitric oxide phosphorylation (peNOS) are 23 hypothesized to reduce insulin-stimulated blood flow in type 2 diabetes (T2D), but studies examining 24 these links in humans are limited. We sought to assess basal and insulin-stimulated endothelial signaling 25 proteins (ET-1 and peNOS) in skeletal muscle from T2D patients. Ten obese T2D (glucose disposal rate 26 (GDR): 6.6±1.6 mg/kg LBM/min) and eleven lean insulin sensitive subjects (Lean GDR: 12.9±1.2 mg/kg 27 LBM/min), underwent a hyperinsulinemic-euglycemic clamp with vastus lateralis biopsies taken before 28 and 60 min into the clamp. Basal biopsies were also taken in eleven medication-naïve, obese, non-T2D 29 subjects. ET-1, peNOS (ser1177), and eNOS protein and mRNA were measured from skeletal muscle 30 samples containing native microvessels. Femoral artery blood flow was assessed by duplex Doppler 31 ultrasound. Insulin-stimulated blood flow was reduced in obese T2D (Lean: +50.7±6.5% baseline, T2D: 32 +20.8±5.2% baseline, p<0.05). peNOS/eNOS content was higher in Lean under basal conditions and 33 although not increased by insulin, remained higher in Lean during the insulin clamp than in obese T2D 34 (p<0.05). ET-1 mRNA and peptide were 2.25±0.50 and 1.52±0.11 fold higher in obese T2D compared to 35
Introduction 50
It is estimated that one third of the U.S. population will have diabetes by 2050 (6). A key 51 39). We are unaware of in-vivo studies in which peNOS and ET-1 expression have been measured in the 76 skeletal muscle of T2D patients before and during hyperinsulinemia. 77
Thus, the purpose of this study was to test the hypothesis that ET-1 content is increased and 78 eNOS phosphorylation (ser1177) decreased in skeletal muscle microvasculature during insulin 79 stimulation in obese individuals with T2D compared to healthy lean insulin sensitive (Lean) individuals. 80
Given that previous studies have demonstrated that individuals across the insulin sensitivity/resistance 81 continuum (Lean, obese, obese T2D) display a progressive impairment in insulin-stimulated blood flow 82 responses (24), we chose to examine the broad ends of this continuum (i.e., Lean and obese T2D patients) 83 to begin to examine potential impairments in endothelial signaling proteins in response to insulin 84 stimulation. We reasoned that this approach would provide important mechanistic insight regarding the 85 production of these signaling proteins in T2D, which may be responsible for decreased glucose uptake, 86 and as such, provide support for the vasculature as a target for therapeutic intervention in patients with 87
T2D. Further, we also compared basal levels of ET-1 and eNOS to age and body weight matched non-88 previously described by our lab (30, 49) . Briefly, approximately 60 to 120 mg of skeletal muscle tissue, 118 and associated micro-vessels perfusing the muscle, was taken from the vastus lateralis. Connective and 119 adipose tissue were removed from the muscle sample and the samples were snap frozen in liquid nitrogen 120 and stored at -80˚C until analyzed. After another 30 minutes rest, a hyperinsulinemic-euglycemic clamp 121 (40µU/m 2 /min) was started (60), with blood glucose samples taken every 5 minutes for the determination 122 of glucose infusion rate. Further, every 30 min blood was drawn into serum separator tubes, spun, and 123 stored at -80̊ C for later insulin and glucose analysis. Given the range of insulin sensitivities, some 124 individuals took longer to obtain a steady glucose infusion rate, which lead to a 2-3 hour range of the 125 insulin clamps. Common femoral artery blood flow was measured via duplex Doppler ultrasound (Logiq 126 P5, GE Medical Systems, Milwaukee, WI) at baseline, ~20 minutes after the baseline muscle biopsy and 127 at minute 45 of the insulin clamp using a 11-Mhz linear array transducer as previously described by our 128 lab (31, 43, 52) . Blood flow (mL min -1 ) was calculated as: blood flow= π x (diameter/2) 2 x V mean x 60, 129 where V mean = mean velocity. Sixty minutes into the hyperinsulinemic-euglycemic clamp a second muscle 130 biopsy was taken as described above. Glucose disposal rate was calculated during the last 45 minutes of 131 the hyperinsulinemic-euglycemic clamp. A hyperinsulinemic-euglycemic clamp was not performed in 1 132 obese T2D due to an inability to obtain IV access and blood flow was not measured in 1 subject due to 133 technical difficulties. Further, due to issues related to blood pressure cuff interference with the IV, blood 134 pressure at baseline and minute 45 of the hyperinsulinemic-euglycemic clamp was only collected in 5 135
Lean and 4 obese T2D subjects. 136
Tissue Analysis 137
Skeletal muscle tissue containing native micro-vessels was assessed for eNOS, peNOS, AKT, and 138 pAKT protein and ET-1 peptide via standard western blotting procedures as performed previously (32). 139
Additional muscle samples from non-T2D obese subjects were also assessed for ET-1 and eNOS under 140 basal conditions and compared to the Lean samples and obese T2D samples. eNOS is not expressed in 141 skeletal muscle (10, 46) , and thus, any protein content that was measured would be from micro-vessels 142 only. Further, to date, no studies have confirmed that ET-1 is produced from skeletal muscle (18). Incontrast, AKT is in muscle tissue and micro-vessels. eNOS and peNOS antibodies were purchased from 144 BD transduction (catalogue number: 610296 and 612392, respectively) and ET-1 from Sigma Aldrich 145 (catalogue number: e166). Briefly, 20 µg of protein homogenate (2 µg/µL) was loaded on 7.5% 146 (eNOS/peNOS and AKT/pAKT) and 15% (ET-1) gels, and transferred to membrane. After blocking for 147 an hour in 5% nonfat milk, membranes were incubated overnight in 5% BSA and the respective primary 148 antibody (1:1000). Following the overnight incubation samples were incubated in 5% milk and their 149 respective secondary antibodies (1:5000) for 1 hour and imaged. A total protein stain was used for the 150 loading control as performed previously (2). The blots were stained with 0.1% Napthol blue black 151 bioreagent (Sigma Aldrich) and washed in 10% acetic acid. Total band intensity for each lane (not 152 including the band of interest) was then used as the loading control for each lane. Importantly, we have 153 tested other ET-1 antibodies from other sources and although they showed bands at the correct molecular 154 weight they also had non-specific bands. However, the ET-1 antibody from Sigma that we utilized 155 showed a clear band at the correct MW range of 24-30 kD. 156
Skeletal muscle tissue containing native micro-vessels was also assessed for NOS3 (eNOS), and 157 pre-pro ET-1 mRNA expression via real time PCR as previously described (16, 37) . Briefly, frozen 158 skeletal muscle samples were homogenized in TRIzol solution using a tissue homogenizer (TissueLyser 159 LT, Qiagen, Valencia, CA). The Qiagen's RNeasy tissue protocol was used to isolate total RNA. Green SMX (BioRad, Hercules, CA) and the appropriate concentrations of gene-specific primers plus 4 170 μL of cDNA template were loaded in a 96-well plate. Samples were run in duplicate as described: 95ºC 171 for 10 min, followed by 40 cycles of 95ºC for 15 s and 60ºC for 45 s. The specificity of PCR primers was 172 verified by a dissociation melt curve. 18S was used as house-keeping control gene. 18S cycle threshold 173 (CT) was not different between the groups and between basal and insulin stimulation conditions. mRNA 174 expression values are presented as 2 ΔCT . ΔCT = 18S CT -gene of interest CT. mRNA levels were 175 normalized to the Lean group under basal conditions. Due to lack of sample, insulin-stimulated skeletal 176 muscle eNOS and ET-1 mRNA were not analyzed in 3 Lean subjects. 177
Blood Analysis 178
Serum samples during the hyperinsulinemic-euglycemic clamp were analyzed for glucose via the 179 glucose oxidase method and insulin via enzyme-linked immunosorbent assays (Immulite 1000 Analyzer, 180
Siemens, Deerfield, IL) as performed previously (31). 181
Statistical Analysis 182
A power analysis was performed on preliminary data generated from our laboratory on peak 183 blood flow responses during the insulin clamp in sedentary individuals with T2D compared to healthy 184 controls. The analysis was conducted with β=0.20m, power=0.8 and α=0.08. From the power analysis it 185 was determined that 8 subjects would allow us to reach statistical significance for insulin stimulated blood 186 flow responses. However, there is a lack of data on endothelial signaling proteins in T2D humans during 187 an insulin clamp, which alludes to the novel nature of this study. Thus, we also increased our sample size 188 (11 lean and 10 obese T2D) to account for this discrepancy. 
Results 200
Subject Characteristics are displayed in Table 1 . Subject medications are listed in Table 2 . 201
Glucose homeostasis -Insulin Sensitivity 202
Fasting blood glucose and HOMA-IR were significantly higher in obese T2D individuals 203 compared to Lean individuals and obese non-T2D subjects (Table 1) 
Skeletal muscle tissue analysis 223
There was a significant main effect for the obese T2D group to have higher pre-pro ET-1 mRNA 224 Because we observed basal, non-insulin-stimulated differences in endothelial signaling proteins 240 between the Lean individuals and obese T2D individuals, we also selected skeletal muscle biopsy samples 241 from a previously published study (30) from 11 obese non-T2D subjects who were age and BMI matched 242 to the obese T2D in this investigation to determine the specific role of T2D independent of obesity alone. 243
The characteristics of the obese-non-T2D individuals are presented in Table 1 However, peNOS/eNOS ( Figure 4E ) protein trended (p=0.054) to be significantly different between the 247 three groups. There was also a trend for statistical significance for ET-1 peptide content to be elevated in 248 the obese individuals and obese T2D individuals compared to Lean individuals ( Figure 4D ) (p=0.064). 249
Insulin sensitivity and endothelin-1 expression correlations 250
GDR was not significantly correlated to ET-1 peptide or mRNA (r= -0.240, p=0.2 and r=-0.335, 251 p=0.4, respectively). Also, HOMA-IR was not correlated to ET-1 peptide or mRNA (r=-0.08, p=0.7 and 252 r=-0.22, p=0.3, respectively). However, fasting blood glucose trended to be significantly correlated to ET-253 between Lean individuals and obese T2D. However, this was not found. Nevertheless, it should be 274 mentioned that there was a trend for ET-1 peptide to increase following insulin stimulation in the T2D 275 condition, but this was not statistically significant (p=0.18) and future studies are necessary to confirm 276 this. Moreover, ET-1 mRNA did not increase following insulin stimulation in the T2D suggesting that 277 there was no increase in the transcription of ET-1 with insulin. 278
Discussion
Our findings of a lack of insulin stimulated activation of peNOS or changes in ET-1 may be 279 different than previous studies for several reasons. First, the insulin levels used in the previous cell culture 280 studies were supraphysiological and likely providing a greater stimulus for increased peNOS and ET-1 281 expression than postprandial levels used in the current study. Further, other cell culture data supports that 282 peNOS is increased within 5 minutes of insulin stimulation (42), so it is possible in the present study that 283 peNOS increased acutely to insulin stimulation then returned towards basal levels following prolonged 284 stimulation. There is also some evidence that supports that prolonged agonist exposure leads to 285 inactivation of eNOS (12, 29). However, if this occurs with prolonged insulin stimulation and/or the time 286 course by which eNOS is inactivated is not known. Protein phosphatase 2A (PP2A) regulates the 287 dephosphorylation of Ser 1177 on eNOS which would inactivate eNOS (12) but we are not aware of any 288 time-course studies examining the activity of PP2A to insulin stimulation. Future studies need to examine 289 the in-vivo time course of peNOS activation and activation of inhibitors of eNOS to determine how these 290 are altered with prolonged insulin stimulation at postprandial concentrations. 291
While we and others demonstrate an increase in leg blood flow following 45-60 minutes of 292 insulin stimulation (31), others report a more variable time of maximal blood flow responses (8, 24) . This 293 may be due to differences in insulin sensitivities, insulin dose and concentration, and duration of 294 exposure. Individuals with insulin resistance have greater plasma insulin responses to meals that also 295 remains elevated for a longer period of time following a meal when compared to lean insulin sensitive 296 individuals. Thus, blood flow (and endothelial signaling proteins) between the lean and the obese T2D 297 individuals may be altered differently following longer periods of insulin stimulation than the 1 hr used in 298 the present study. Indeed, previous reports by Kashyap et al. (17) demonstrate in non-T2D subjects that 299 significant increases in eNOS expression are induced following 4 hours of insulin stimulation, while this 300 duration of insulin infusion did not change eNOS in T2D subjects. However, in-vitro studies in 301 endothelial cells indicate that insulin stimulated eNOS phosphorylation occurs at the onset of insulin 302 exposure (42) and this is rapidly changed back to basal levels through a putative feedback control system 303 (12, 29). We measured eNOS and ET-1 in the microvessels of skeletal muscle biopsies at 1 hour, a time-304 point when our preliminary studies demonstrated that insulin infusion caused a significant increase in 305 blood flow compared to baseline. However, eNOS phosphorylation was not increased with 1 hour of 306 insulin infusion. Given the already previously mentioned findings, it is possible that either a shorter or 307 longer duration of insulin infusions would have revealed a significant change in peNOS in either of the 308 groups. Future studies need to address this. 309
In the present study, obese T2D individuals had significantly elevated basal eNOS protein content 310 compared to the Lean individuals but the obese T2D individuals did not express greater peNOS. This is in 311 contrast to previous reports comparing weight matched controls to T2D patients that reported decreased 312 (53) and no differences in basal eNOS (17) expression in T2D patients. The greater elevations of eNOS 313 protein content in the obese T2D individuals in the present study may be due in part to chronic greater 314 basal and post-prandial insulin concentrations, a stimulus known to increase eNOS content (22). Thus, it 315 is possible that the elevation in eNOS in obese T2D is a compensatory mechanism to sustain similar 316 amounts of peNOS compared to non-T2D individuals. Aged rodents (55) and humans (11) also display 317 increased eNOS expression which is postulated to counter the reduced NO bioavailability and NO 318 mediated vasodilation shown in aged population, thus it is possible the same phenomenon occurs with 319 obesity and T2D. 320
As previously stated, a key finding was that the obese T2D showed significantly higher basal 321 peptide content of the potent vasoconstrictor ET-1 than the Lean subjects. Likewise, previous studies 322 have demonstrated elevated basal plasma levels of ET-1 in individuals with T2D compared to controls 323 (45). Since ~80% of endothelin-1 is secreted on the abluminal side and putatively signals locally through 324 a paracrine fashion (58), plasma ET-1 is not considered the best marker of cellular levels of endothelial 325 ET-1 concentrations. Thus, in this regard, direct measures of ET-1 in the vasculature of skeletal muscle 326 homogenate provide an advantage over blood samples. Importantly, previous studies have demonstrated 327 that ET-1 blockade significantly increased blood flow to a greater extent in individuals with T2D 328 compared to non T2D individuals (27, 28, 47, 50) suggesting that individuals with T2D have greater ET-1 329 mediated basal vasoconstrictor tone. These studies, and others (7, 40, 44, 51) , demonstrate the important 330 role of obesity and insulin resistance in altering ET-1 mediated vasoconstriction. Therefore, the greater 331 basal ET-1 content found in this study and associated vasoconstriction, combined with previous inhibitor 332 studies, suggests that elevated ET-1 may partially explain the blunted insulin-stimulated blood flow 333 response in the obese T2D individuals. 334
Since we demonstrated significant elevations in basal levels of ET-1 and eNOS in the obese T2D 335 compared to the Lean individuals, we were interested in understanding if these effects were due to the 336 pathology of T2D or were caused by the obese state or age differences in our Lean subjects and obese 337 T2D subjects. Thus, we examined ET-1 peptide from skeletal muscle biopsy samples collected from a 338 previously published paper (30) in subjects that were age and BMI matched to the obese T2D subjects in 339 the current study. These data showed that obese and obese T2D have similar ET-1 peptide levels, 340 alluding to the possibility that elevated ET-1 levels in the vasculature occur during the obese state and 341 preclude the development of T2D. Similarly, Kim et al. (19) showed that high fat fed, obese mice 342 displayed insulin resistance in the vasculature before skeletal muscle, liver, or adipose tissue suggesting 343 that impairments in the vasculature occur early in the development of insulin resistance. Further, work 344 from our group (33) has demonstrated that sedentary obese, insulin resistant OLETF rats, prior to the 345 development of T2D, have greater insulin-stimulated vasodilation to ET-1 blockade compared to their 346 sedentary insulin sensitive counterparts, providing further evidence that up regulation of ET-1 occurs 347 early in the progression of insulin resistance and likely prior to T2D. 348
Obesity has been shown to result in increased ET-1 peptide and prepro-ET-1 gene expression (5, 349 34, 57). Thus, it is likely that obesity (and hyperglycemia) are both driving the trend for higher ET-1 350 expression in the obese and obese T2D compared to Lean. Endothelin-1 expression increases in 351 endothelial cells exposed to hyperglycemic conditions (14, 59). Correlational analysis revealed that 352 fasting blood glucose was significantly correlated to ET-1 mRNA and trended to be correlated to ET-1 353 peptide, further suggesting a link between glucose and ET-1 expression. Given that the obese T2D 354 individuals were on antidiabetic medications to treat hyperglycemia, ET-1 expression may be reduced 355 compared to an obese T2D that is not treated. Insulin also increases endothelin-1 via MAPK mediated 356 pathways (15, 38). Thus, chronic fasting hyperinsulinemia is likely another important contributor of theincreased basal ET-1 in obese T2D compared to Lean subjects, however, as already stated, we did not see 358 evidence that acute insulin stimulation increases ET-1 mRNA or peptide in either subject group.
359
To summarize, we demonstrated for the first time in humans that skeletal muscle phosphorylation 360 of eNOS does not significantly increase following 1 hour of post-prandial levels of insulin in either Lean 361 individuals or obese T2D individuals. However, significant increases in peNOS/eNOS were found in 362
Lean individuals compared to obese T2D individuals in the basal, non-insulin-stimulated state. Further, 363 basal, non-insulin-stimulated levels of ET-1 were elevated in obese T2D individuals, but were not altered 364 with 60 minutes of insulin stimulation. Additionally, we provide evidence that elevated ET-1 peptide 365 may occur in obesity prior to the development of T2D. While sex differences were not analyzed in the 366 present study due a low sample size, future studies should investigate whether sex specific differences 367 played a role in these findings. Further, given that our lean subjects were younger than our obese and 368 obese T2D subjects, future studies should examine the impact of aging on these parameters. 369
In conclusion, the blunted leg blood flow response following 60 minutes of hyperinsulinemia in 370 obese T2D individuals in the present study is not due to impaired production/activation of eNOS and ET-371 1 to insulin stimulation, but may be due to chronically higher basal levels of ET-1 content and expression 372 and reduced peNOS/eNOS present at rest in T2D. 373 (12PRE12080242). J.P. was supported by NIH R21DK105368 and K01HL125503. C.M. was supported 383 by 1K08HL129074-01. 384
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